Follicular lymphoma is a cancer that affects white blood cells called lymphocytes. They help your body fight infections. There are two types of lymphomas: Hodgkin's and non-Hodgkin's, based on the ...

When I started receiving treatment for follicular lymphoma, I wasn’t sure what to expect regarding treatment — and a lot of things were unexpected. I’ve heard that trauma doesn’t make people stronger, ...

The #Gators have come up with a turnover in 10 straight games after the second pick of the season by Trikweze Bridges. The Clemson safety led all qualified ACC safeties with an 89.8 Pro Football Focus ...

Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers—follicular lymphoma and marginal zone ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

Newer-generation Bruton's tyrosine kinase (BTK) inhibitors have found a place in the management of follicular lymphoma, a malignancy where the first-generation drug ibrutinib (Imbruvica ...

Remission indicates symptom disappearance, not a cure, especially in chronic diseases like follicular lymphoma. Blood cancers are challenging to eradicate due to their systemic nature, requiring ...

As with all NFL draft picks, the social media reactions came fast and furious when the Tampa Bay Buccaneers selected Emeka Egbuka at No. 19. And, as usual with first-round picks, most were positive. A ...

Epizyme has scored an important FDA win after the regulator approved its Tazverik (tazemetostat) in follicular lymphoma. Tazverik is already approved in patients with epithelioid sarcoma, a rare ...

But that doesn't mean he keeps his bias separate, as Parsons has shared his emotional reactions to how the draft has played out so far in relation to how it affects his team. Early in the first ...

In this 3-year updated analysis, the ORR was 77.8%, with 60.0% of patients achieving a CR with mosunetuzumab. Updated results from the pivotal phase 1/2 trial of mosunetuzumab in patients with ...